<DOC>
	<DOCNO>NCT01445054</DOCNO>
	<brief_summary>Background : - Some breast cancer cell specific protein ( receptor ) surface make tumor grow faster normal cell . One receptor call HER2/neu . - An FDA-approved drug call Herceptin attache HER2/neu present cancer cell . - Indium-Herceptin agent tiny amount radioactivity call Indium attach tiny amount Herceptin . Objectives : -To see Indium-Herceptin provide information characteristic breast cancer woman whose tumor express HER2/neu whose tumor . Eligibility : -Women 18 year old primary metastatic breast cancer receive treatment herceptin least 6 month enrollment study . Design : - Tissue patient original breast tumor biopsy analyze HER2/neu status . - Patients physical examination review medical record . - Patients receive injection Indium-Herceptin , follow scan gamma camera detect radioactivity Indium-Herceptin . - Patients return clinic 1 , 2 , 3 7 day later repeat image determine best time image injection Indium-Herceptin . - Blood sample obtain every day scan monitor effect , , Indium-Herceptin see fast agent leave body .</brief_summary>
	<brief_title>111 Indium CHX-A DTPA Trastuzumab ( Indium-Herceptin ) Imaging Breast Cancer</brief_title>
	<detailed_description>Background : - Trastuzumab ( Herceptin ) , target HER2 ( aka : neu , ErbB2 , c-erb-B2 ) surface cancer cell use treatment breast cancer overexpress HER2/Neu ( Erb2 ) . It also demonstrate malignancy express HER2/Neu ( Erb2 ) . - Radiolabeling trastuzumab could allow human biodistribution study , noninvasive assessment HER2/Neu ( Erb2 ) expression , identification HER2/Neu ( Erb2 ) positive metastasis , monitor treatment response establishment dosimetry future radioimmunotherapy . - We develop chelate form trastuzumab , CHX-A DTPA-trastuzumab , bind number radioisotope include ( 111 ) In , ( 212 ) , ( 213 ) Bi , ( 212 ) Pb ( 86 ) , ( 90 ) Y ( 177 ) Lu alpha , beta gamma emission image therapy . - We believe agent safe base low dose trastuzumab ( maximum 200 mcg protein less than1 % typical loading dose trastuzumab 70 Kg human ) low dose radioactivity ( 5mCi ) . - Whereas trastuzumab therapy generally useful tumor highly express HER2/Neu ( Erb2 ) , ( 111 ) In-CHX-A DTPA trastuzumab ( henceforth ( 111 ) Indium-trastuzumab ) image tumor highly express HER2/Neu ( Erb2 ) also tumors poorly express HER2/Neu ( Erb2 ) document preclinical data . Objectives : -The primary objective compare uptake 111Indium trastuzumab HER2/Neu ( Erb2 ) status tumor determine IHC Eligibility : - Participants history primary metastatic cancer ( melanoma , basal cell carcinoma , sarcoma lymphoma ) know solid tumor size great equal 1.5 cm . - Availability HER2/Neu ( Erb2 ) expression immunohistochemistry ( IHC ) pathology biopsy specimen provide analysis make . Design : - The design pilot trial follow concept Phase 0 Exploratory IND ( xIND ) study . - Participants know malignancy great equal 1.5cm know HER2/Neu ( ErbB2 ) tumor status ( 0 , 1+ , 2+ 3+ ) IHC FISH . - After receive 5 mCi ( 111 ) Indium-trastuzumab , participant undergo gamma camera scan approximately 24-72 hour injection . In subject , additional imaging session may require 24 hour first set image physiologic bowel clearance variable may obscure lesion interest initial scan . - We accrue 20 participant study . - A total 8 blood sample ( 4 lab test 4 pharmacokinetics ) obtain participant establish toxicity pharmacokinetics clearance . - Images correlate IHC status use tumor background ratio optimal scan strategy regard HER2/neu ( ErbB2 ) expression determine . - Participants undergo therapy think target effect HER2 option undergo repeat image follow therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Pentetic Acid</mesh_term>
	<criteria>INCLUSION CRITERIA : Participant must histological confirmation primary metastatic cancer melanoma , basal cell carcinoma , sarcoma , lymphoma . Primary tumor metastatic focus must 1.5cm great diameter establish palpation , ultrasound , mammography , CT MRI . Participant must 18 year old . Availability tumor tissue ( either initial primary tumor current tumor lesion ) perform IHC FISH analysis HER2/Neu ( Erb2 ) Chemistry CBC parameter : serum creatinine less equal 1.4mg/dl . SGOT SGPT less equal 3 time upper limit normal ; total bilirubin , less equal 2 time upper limit normal 3.0 mg/dl patient Gilbert syndrome ; platelet count must great 100,00 . ECOG Performance score 0 1 . Ability provide inform consent . Negative serum pregnancy test ( within 48 hour image agent injection ) woman child bear age willingness use contraception ( barrier , abstinence , nonhormonal ) 3 week injection ( 111 ) Indium trastuzumab participant child bearing age . EXCLUSION CRITERIA : Known allergy trastuzumab . Pregnant lactating woman . Participants enrollment would significantly delay ( great 2 week ) schedule standard care therapy . Participants active second malignancy ( exclude treat basal cell skin carcinoma ) . History cardiac disease ( myocardial infarction , arrhythmias require therapy , symptomatic valvular disease , cardiomyopathy , pericarditis ) . Participants coexist medical psychiatric condition likely interfere study procedure and/or result . Participants severe claustrophobia . A participant need nuclear medicine scan PET scan part workup enroll scan complete . Gammacamera table restriction preclude scan participant great 350 lb ( 160 Kg ) With exception AT13387 PUH71 , Ad5f35HER2ECTM transduce autologous dendritic cell vaccine participant receive another experimental drug within 14 day prior study enrollment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 22, 2016</verification_date>
	<keyword>111 Indium Trastuzumab Imaging</keyword>
	<keyword>PET</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>